Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year Low – Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares hit a new 52-week low on Friday . The company traded as low as $19.11 and last traded at $19.16, with a volume of 42940 shares changing hands. The stock had previously closed at $19.94.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GPCR. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target on the stock. William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

The firm’s 50 day moving average is $24.34 and its two-hundred day moving average is $31.35. The firm has a market capitalization of $1.10 billion, a P/E ratio of -25.78 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Deep Track Capital LP increased its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after acquiring an additional 1,579,492 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Structure Therapeutics by 196.5% during the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after purchasing an additional 602,609 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in shares of Structure Therapeutics in the fourth quarter valued at about $13,560,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.